Gossamer Bio’s (GOSS) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $15.00 price target on the stock.

GOSS has been the topic of a number of other research reports. Wedbush restated an outperform rating and issued a $6.00 price target on shares of Gossamer Bio in a report on Wednesday, March 6th. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Wednesday, March 6th. Finally, The Goldman Sachs Group reduced their target price on Gossamer Bio from $9.00 to $8.00 and set a buy rating on the stock in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $8.05.

Gossamer Bio Stock Performance

GOSS opened at $1.17 on Wednesday. The stock has a market cap of $263.93 million, a P/E ratio of -0.84 and a beta of 1.73. The company has a debt-to-equity ratio of 3.14, a current ratio of 5.94 and a quick ratio of 5.94. The stock’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $0.91. Gossamer Bio has a 1-year low of $0.45 and a 1-year high of $1.88.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). As a group, equities analysts anticipate that Gossamer Bio will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GOSS. Atom Investors LP purchased a new position in shares of Gossamer Bio during the 4th quarter worth $28,000. Bayesian Capital Management LP purchased a new position in shares of Gossamer Bio during the 2nd quarter worth $29,000. Dark Forest Capital Management LP purchased a new position in shares of Gossamer Bio during the 1st quarter worth $30,000. Virtu Financial LLC purchased a new position in shares of Gossamer Bio during the 4th quarter worth $30,000. Finally, AQR Capital Management LLC purchased a new position in shares of Gossamer Bio during the 4th quarter worth $31,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.